do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline Can patients take and together? SGLT-2 inhibitors, GLP-1 receptor agonists,
Description
Its Phase 3 data show double-digit weight-loss, deep HbA 1c cuts, and promising cardiometabolic markersall while regulators on two continents fast-track review

Curr Diab Rep 22:317332

(2025, June 10)

Wilson CH, Ali ES, Scrimgeour N, Martin AM, Hua J, Tallis GA, et al

Mowl AD, Grogg JA, Klein J

In particular, they have shown a reduction of major adverse cardiovascular events (MACE) in diabetic patients at high cardiovascular risk [23,24,25,26,27,28,29,30]
